title: [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
abstract: Liver cirrhosis induced by HBV and HCV infections is the main risk factor for the development of hepatocellular carcinoma (HCC). Therefore, prevention of chronic infection with hepatitis viruses and prevention of the development of cirrhosis are essential for the primary prevention of HCC. A consequent vaccination program for HBV is suitable to reduce the rate of infections and the HCC-associated mortality. Since no vaccine is available for HCV, the reduction of risky behaviour and the improvement of hygiene standards are the mainstays for prevention of HCV. An efficient antiviral therapy aimed at the durable suppression of the viral load reduces the risk of progression to cirrhosis and development of HCC in precirrhotic stages of chronic HBV or HCV infections. In cirrhotic patients, the risk of developing HCC remains elevated even if a sustained virological response is achieved, thus requiring further screening with the intention of the early detection of HCC. It is too early to judge whether virological nonresponders profit from continued antiviral therapy. Therefore, the early diagnosis of chronic HBV or HCV infection is the single most important factor for the prevention of HCC. Secondary prevention after surgical resection or local ablative therapy may reduce the frequency of late recurrence. Liver transplantation is today the most effective measure of secondary prevention for selected patients with HCC. Due to its antiproliferative effects, the immunosuppressive drug sirolimus may play a role for secondary prevention of HCC following transplantation.
authors.affiliation: Med. Klinik m.S. Hepatologie und Gastroenterologie, Charité, CVK, Berlin. eckart.schott@charite.de
authors.forename: E
authors.initials: E
authors.lastname: Schott
authors.forename: A
authors.initials: A
authors.lastname: Bergk
authors.forename: T
authors.initials: T
authors.lastname: Berg
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000517:prevention & control*; D002648:Child; D005260:Female; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D008103:Liver Cirrhosis / Q000517:prevention & control; D008113:Liver Neoplasms / Q000209:etiology / Q000517:prevention & control*; D016031:Liver Transplantation; D008297:Male; D015201:Meta-Analysis as Topic; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012309:Risk-Taking
chemical_list: D000998:Antiviral Agents; D017325:Hepatitis B Vaccines